WO2001014588A1 - Isogenes cibles de medicament: polymorphismes dans le gene de la chaine beta du recepteur e d'immunoglobuline - Google Patents
Isogenes cibles de medicament: polymorphismes dans le gene de la chaine beta du recepteur e d'immunoglobuline Download PDFInfo
- Publication number
- WO2001014588A1 WO2001014588A1 PCT/US2000/022175 US0022175W WO0114588A1 WO 2001014588 A1 WO2001014588 A1 WO 2001014588A1 US 0022175 W US0022175 W US 0022175W WO 0114588 A1 WO0114588 A1 WO 0114588A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- igerb
- gene
- seq
- haplotype
- polymoφhic
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 205
- 108010073816 IgE Receptors Proteins 0.000 title claims abstract description 28
- 102000009438 IgE Receptors Human genes 0.000 title claims abstract description 28
- 102000054765 polymorphisms of proteins Human genes 0.000 title abstract description 4
- 239000003596 drug target Substances 0.000 title description 3
- 102000054766 genetic haplotypes Human genes 0.000 claims abstract description 136
- 239000002773 nucleotide Substances 0.000 claims abstract description 127
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 127
- 238000000034 method Methods 0.000 claims abstract description 104
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 30
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 30
- 239000002157 polynucleotide Substances 0.000 claims abstract description 30
- 239000000203 mixture Substances 0.000 claims abstract description 26
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims description 90
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 claims description 82
- 108091034117 Oligonucleotide Proteins 0.000 claims description 75
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims description 68
- 102000004169 proteins and genes Human genes 0.000 claims description 62
- 239000012634 fragment Substances 0.000 claims description 56
- 235000018102 proteins Nutrition 0.000 claims description 56
- 230000000295 complement effect Effects 0.000 claims description 54
- 229940113082 thymine Drugs 0.000 claims description 41
- 108700028369 Alleles Proteins 0.000 claims description 38
- 229940104302 cytosine Drugs 0.000 claims description 34
- 235000001014 amino acid Nutrition 0.000 claims description 32
- 230000014509 gene expression Effects 0.000 claims description 32
- 238000003205 genotyping method Methods 0.000 claims description 32
- 230000004044 response Effects 0.000 claims description 31
- 150000007523 nucleic acids Chemical class 0.000 claims description 29
- 102000039446 nucleic acids Human genes 0.000 claims description 28
- 108020004707 nucleic acids Proteins 0.000 claims description 28
- 239000003814 drug Substances 0.000 claims description 24
- 108020004414 DNA Proteins 0.000 claims description 22
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 22
- 229940079593 drug Drugs 0.000 claims description 21
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 19
- 229930024421 Adenine Natural products 0.000 claims description 18
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims description 18
- 229960000643 adenine Drugs 0.000 claims description 18
- 150000001413 amino acids Chemical class 0.000 claims description 18
- 101000798429 Pinus strobus Putative 2-Cys peroxiredoxin BAS1 Proteins 0.000 claims description 17
- -1 PS12 Chemical compound 0.000 claims description 15
- 241001465754 Metazoa Species 0.000 claims description 13
- 238000006243 chemical reaction Methods 0.000 claims description 12
- 230000027455 binding Effects 0.000 claims description 11
- 239000002299 complementary DNA Substances 0.000 claims description 11
- 230000008685 targeting Effects 0.000 claims description 11
- 230000001105 regulatory effect Effects 0.000 claims description 10
- 229920001184 polypeptide Polymers 0.000 claims description 9
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 9
- 230000009261 transgenic effect Effects 0.000 claims description 7
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 102000053602 DNA Human genes 0.000 claims description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 3
- 235000004279 alanine Nutrition 0.000 claims description 3
- 235000018417 cysteine Nutrition 0.000 claims description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 3
- 230000001419 dependent effect Effects 0.000 claims description 3
- 230000001747 exhibiting effect Effects 0.000 claims description 3
- 229930182817 methionine Natural products 0.000 claims description 3
- 238000012545 processing Methods 0.000 claims description 3
- 238000004891 communication Methods 0.000 claims description 2
- 238000012216 screening Methods 0.000 claims description 2
- 241000282414 Homo sapiens Species 0.000 abstract description 19
- 239000013615 primer Substances 0.000 description 84
- 238000003752 polymerase chain reaction Methods 0.000 description 36
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 33
- 210000004027 cell Anatomy 0.000 description 32
- 230000002441 reversible effect Effects 0.000 description 31
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 28
- 230000000875 corresponding effect Effects 0.000 description 27
- 238000011282 treatment Methods 0.000 description 26
- 108010029485 Protein Isoforms Proteins 0.000 description 23
- 102000001708 Protein Isoforms Human genes 0.000 description 23
- 239000000047 product Substances 0.000 description 23
- 201000010099 disease Diseases 0.000 description 22
- 229940024606 amino acid Drugs 0.000 description 17
- 108020004999 messenger RNA Proteins 0.000 description 15
- 239000000523 sample Substances 0.000 description 14
- 230000002068 genetic effect Effects 0.000 description 13
- 238000004458 analytical method Methods 0.000 description 12
- 210000000349 chromosome Anatomy 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 230000006870 function Effects 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 238000003556 assay Methods 0.000 description 11
- 239000011324 bead Substances 0.000 description 11
- 239000013598 vector Substances 0.000 description 11
- 238000009396 hybridization Methods 0.000 description 10
- 206010003645 Atopy Diseases 0.000 description 9
- 230000003321 amplification Effects 0.000 description 9
- 230000008901 benefit Effects 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 9
- 239000013604 expression vector Substances 0.000 description 9
- 238000003199 nucleic acid amplification method Methods 0.000 description 9
- 208000006673 asthma Diseases 0.000 description 8
- 239000012472 biological sample Substances 0.000 description 8
- 230000001404 mediated effect Effects 0.000 description 8
- 102000005962 receptors Human genes 0.000 description 8
- 108020003175 receptors Proteins 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 238000013459 approach Methods 0.000 description 7
- 210000004899 c-terminal region Anatomy 0.000 description 7
- 210000005220 cytoplasmic tail Anatomy 0.000 description 7
- 230000001086 cytosolic effect Effects 0.000 description 7
- 238000012163 sequencing technique Methods 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 238000004422 calculation algorithm Methods 0.000 description 6
- 230000028993 immune response Effects 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 206010020751 Hypersensitivity Diseases 0.000 description 5
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 239000013566 allergen Substances 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 238000002405 diagnostic procedure Methods 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 210000003630 histaminocyte Anatomy 0.000 description 5
- 239000002751 oligonucleotide probe Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 238000013518 transcription Methods 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 108091026890 Coding region Proteins 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 108700024394 Exon Proteins 0.000 description 4
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 208000026935 allergic disease Diseases 0.000 description 4
- 230000007815 allergy Effects 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 239000000074 antisense oligonucleotide Substances 0.000 description 4
- 238000012230 antisense oligonucleotides Methods 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 230000002596 correlated effect Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000003018 immunoassay Methods 0.000 description 4
- 102000018358 immunoglobulin Human genes 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000026731 phosphorylation Effects 0.000 description 4
- 238000006366 phosphorylation reaction Methods 0.000 description 4
- 239000002987 primer (paints) Substances 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 238000013519 translation Methods 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 108020004635 Complementary DNA Proteins 0.000 description 3
- 239000003155 DNA primer Substances 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 102000009109 Fc receptors Human genes 0.000 description 3
- 108010087819 Fc receptors Proteins 0.000 description 3
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- 108091092195 Intron Proteins 0.000 description 3
- 108091081021 Sense strand Proteins 0.000 description 3
- 108091036066 Three prime untranslated region Proteins 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000008827 biological function Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 210000003527 eukaryotic cell Anatomy 0.000 description 3
- 230000007614 genetic variation Effects 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 238000005457 optimization Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000011535 reaction buffer Substances 0.000 description 3
- 238000003259 recombinant expression Methods 0.000 description 3
- 230000006798 recombination Effects 0.000 description 3
- 238000005215 recombination Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 235000002374 tyrosine Nutrition 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 2
- 108091033380 Coding strand Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 208000001718 Immediate Hypersensitivity Diseases 0.000 description 2
- 102000004388 Interleukin-4 Human genes 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 108091027974 Mature messenger RNA Proteins 0.000 description 2
- 108091092878 Microsatellite Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- WGZDBVOTUVNQFP-UHFFFAOYSA-N N-(1-phthalazinylamino)carbamic acid ethyl ester Chemical compound C1=CC=C2C(NNC(=O)OCC)=NN=CC2=C1 WGZDBVOTUVNQFP-UHFFFAOYSA-N 0.000 description 2
- 229920002594 Polyethylene Glycol 8000 Polymers 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- 108020005038 Terminator Codon Proteins 0.000 description 2
- 108700019146 Transgenes Proteins 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 241000700618 Vaccinia virus Species 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 238000007844 allele-specific PCR Methods 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 210000003651 basophil Anatomy 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000007878 drug screening assay Methods 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 210000001671 embryonic stem cell Anatomy 0.000 description 2
- 208000024711 extrinsic asthma Diseases 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000002055 immunohistochemical effect Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 229940028885 interleukin-4 Drugs 0.000 description 2
- 229940100601 interleukin-6 Drugs 0.000 description 2
- 238000007834 ligase chain reaction Methods 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- QRGBOABBMKYMLG-UXHICEINSA-N n-({(2s)-1-[(3r)-3-amino-4-(3-chlorophenyl)butanoyl]pyrrolidin-2-yl}methyl)-3-(methylsulfonyl)benzamide Chemical compound CS(=O)(=O)C1=CC=CC(C(=O)NC[C@H]2N(CCC2)C(=O)C[C@H](N)CC=2C=C(Cl)C=CC=2)=C1 QRGBOABBMKYMLG-UXHICEINSA-N 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- FBNHIFPJXGPDIP-UHFFFAOYSA-N pentasulfane Chemical compound SSSSS FBNHIFPJXGPDIP-UHFFFAOYSA-N 0.000 description 2
- 238000009521 phase II clinical trial Methods 0.000 description 2
- 230000000865 phosphorylative effect Effects 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000004043 responsiveness Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 238000010181 skin prick test Methods 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 102000009076 src-Family Kinases Human genes 0.000 description 2
- 108010087686 src-Family Kinases Proteins 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 108091005703 transmembrane proteins Proteins 0.000 description 2
- 102000035160 transmembrane proteins Human genes 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 230000009959 type I hypersensitivity Effects 0.000 description 2
- 150000003668 tyrosines Chemical class 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 241000238876 Acari Species 0.000 description 1
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 208000002109 Argyria Diseases 0.000 description 1
- 208000012657 Atopic disease Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010066091 Bronchial Hyperreactivity Diseases 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 102000001327 Chemokine CCL5 Human genes 0.000 description 1
- 108010055166 Chemokine CCL5 Proteins 0.000 description 1
- 102100026735 Coagulation factor VIII Human genes 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 238000011537 Coomassie blue staining Methods 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 238000007399 DNA isolation Methods 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 201000003542 Factor VIII deficiency Diseases 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 102100038009 High affinity immunoglobulin epsilon receptor subunit beta Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 1
- 101000878594 Homo sapiens High affinity immunoglobulin epsilon receptor subunit beta Proteins 0.000 description 1
- 101000829171 Hypocrea virens (strain Gv29-8 / FGSC 10586) Effector TSP1 Proteins 0.000 description 1
- 102000009490 IgG Receptors Human genes 0.000 description 1
- 108010073807 IgG Receptors Proteins 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 102000043131 MHC class II family Human genes 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 1
- 206010028116 Mucosal inflammation Diseases 0.000 description 1
- 102000010645 MutS Proteins Human genes 0.000 description 1
- 108010038272 MutS Proteins Proteins 0.000 description 1
- 206010028748 Nasal obstruction Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 108010067902 Peptide Library Proteins 0.000 description 1
- 108091093037 Peptide nucleic acid Proteins 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108700026226 TATA Box Proteins 0.000 description 1
- 108700009124 Transcription Initiation Site Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 108091023045 Untranslated Region Proteins 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047924 Wheezing Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000002141 anti-parasite Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000009830 antibody antigen interaction Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000003096 antiparasitic agent Substances 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 238000013473 artificial intelligence Methods 0.000 description 1
- 238000013528 artificial neural network Methods 0.000 description 1
- 229940127225 asthma medication Drugs 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 230000035578 autophosphorylation Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000003935 denaturing gradient gel electrophoresis Methods 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 208000022602 disease susceptibility Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 102000054767 gene variant Human genes 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 238000011478 gradient descent method Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 239000012133 immunoprecipitate Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000012750 in vivo screening Methods 0.000 description 1
- 238000009399 inbreeding Methods 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 239000012212 insulator Substances 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 description 1
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 238000013178 mathematical model Methods 0.000 description 1
- 210000000350 mc(t) Anatomy 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 231100000150 mutagenicity / genotoxicity testing Toxicity 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 238000003499 nucleic acid array Methods 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000000123 paper Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 238000009522 phase III clinical trial Methods 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 102200064919 rs569108 Human genes 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 238000009589 serological test Methods 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 239000013605 shuttle vector Substances 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 238000002922 simulated annealing Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 206010041232 sneezing Diseases 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 208000013931 susceptibility to asthma Diseases 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- PIEPQKCYPFFYMG-UHFFFAOYSA-N tris acetate Chemical compound CC(O)=O.OCC(N)(CO)CO PIEPQKCYPFFYMG-UHFFFAOYSA-N 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Definitions
- This invention relates to variation in genes that encode pharmaceutically important proteins.
- this invention provides genetic variants of the human Immunoglobulin E receptor beta chain (IGERB) gene and methods for identifying which variant(s) of this gene is/are possessed by an individual.
- IGERB Immunoglobulin E receptor beta chain
- a target protein currently used to screen drugs typically is expressed by a gene cloned from an individual who was arbitrarily selected.
- the nucleotide sequence of a particular gene may vary tremendously among individuals.
- Subtle alteration(s) in the primary nucleotide sequence of a gene encoding a target protein may be manifested as significant variation in expression of or in the structure and/or function of the protein. Such alterations may explain the relatively high degree of uncertainty inherent in treatment of individuals with drugs whose design is based upon a single representative example of the target.
- haplotype The organization of single nucleotide variations (polymo ⁇ hisms) in the primary sequence of a gene into one of the limited number of combinations that exist as units of inheritance is termed a haplotype. Each haplotype therefore contains significantly more information than individual haplotype. Each haplotype therefore contains significantly more information than individual unorganized polymo ⁇ hisms. Haplotypes provide an accurate measurement of the genomic variation in the two chromosomes of an individual.
- haplotype will provide a superior genetic marker for the phenotype (Clark AG et al. 1998 supra; Ulbrecht M et al. 2000, supra; Rua ⁇ o G & Stephens JC Gen EngNews 19 (21), December 1999). Analysis of the association between each observed haplotype and a particular phenotype permits ranking of each haplotype by its statistical power of prediction for the phenotype. Haplotypes found to be strongly associated with the phenotype can then have that positive association confirmed by alternative methods to minimize false positives.
- IGERB Immunoglobulin E receptor beta chain
- IGER The high affinity IgE receptor
- OMIM 147138
- Fc receptors initiate immune system reactions in normal immunity, allergies, antibody-mediated tumor recognition, and autoimmune diseases such as arthritis.
- IGER mediates IgE- dependent peripheral and systemic anaphylaxis, regulates IgE metabolism, and plays a role in the growth and differentiation of various cells of the immune system.
- IGER initiates the immediate hypersensitivity response from mast cells and basophils, and evidence indicates that this receptor is involved in antiparasitic reactions from platelet and eosinophils, and in antigen delivery to dendritic cells for MHC class II presentation pathways activating T cells. Moreover, IGER exerts a regulatory effect on IgE production, as well as differentiation and growth of mast cell and B-lymphocytes. Stimulation of IGER initiates a cascade of events resulting in a number of cellular events. For example, mast cells release inflammatory mediators, such as histamine.
- Cytokines are also released, particularly interleukin 4 (IL-4), which is critical in the B-cell switching and IgE synthesis pathways, as well as a feed-back up-regulation of IGER synthesis.
- IGER stimulation also induces expression and functions of other mast cell surface receptors, such as CD40, involved in immune cell growth and differentiation, as well as IgE metabolism.
- Other factors whose expression and/or secretion are regulated by IGER include, interleukin 6 (IL-6), tissue necrosis factor alpha (TNF ⁇ ), RANTES, and serotonin, among others.
- IGER is a tetrameric transmembrane protein containing an alpha, beta, and two disulfide- bonded gamma polypeptides (gamma subunit).
- the alpha subunit, IGERA binds IgE with high affinity (Kd ⁇ 109-1010M) and can be secreted as a soluble IgE-binding fragment.
- the gamma subunit, IGERG mediates receptor assembly and signal transduction, and is a common component of other Fc receptors, including the high-affinity and low-affinity IgG receptors, and the TCR/CD3 T-cell receptor complex.
- IGERB beta subunit
- the alpha subunit of IGER consists of a C-terminal cytoplasmic tail, a single transmembrane region, and an N-terminal extracellular region divided into two large immunoglobulin (lg) domains.
- the lg domains are each 85 amino acids in length, and are bent at an acute angle to form a convex binding site for IgE.
- the second domain has a prominent loop that projects above the domain and is a site of interaction with IgE.
- IGERB is a four transmembrane protein with N-terminal and C-terminal cytoplasmic tails.
- the N-terminal cytoplasmic domain interacts with the cytoplasmic domains of the IGERG subunits.
- IGERG The C-terminal cytoplasmic tail of IGERB associates with the cytoplasmic tail of the alpha subunit.
- IGERG has a short extracellular N-terminal tail, a single transmembrane region, and a C-terminal cytoplasmic domain.
- IGERB and IGERG have immunoreceptor tyrosine activation motifs (ITAM) in their cytoplasmic domains.
- ITAM immunoreceptor tyrosine activation motifs
- the IGERB ITAM appears in the C-terminal cytoplasmic domain.
- Receptor subunit cross-linking activates the src kinase, Lyn, associated with the IGERB ITAM, in turn phosphorylating two tyrosine residues in the ITAM.
- This event activates the src kinase, Syk, associated with the IGERG ITAM, phosphorylating the ITAM tyrosines in that subunit.
- the gene for the beta subunit of the IgE receptor is located on human chromosome 1 lql3 (Szepetowski and Gaudray, Genomics 19:399-400, 1989; Young et al., J. Med. Genet. 29:236-238 1992; Sandford et al., Lancet 341:332-334, 1993).
- the gene spans approximately 10 kilobase pairs (kb) of genomic DNA and consists of seven exons encoding 244 amino acids (Kuster et al., J. Biol. Chem. 267:12782-12787, 1992).
- Reference sequences for the IGERB gene comprising 11,298 nucleotides (SEQ ID NO: 1; GenBank Accession No.
- coding sequence, and protein are shown in Figs. 1, 2, and 3, respectively.
- Significant features reported for the IGERB gene and its encoded protein include: a canonical TATA box located at nucleotide position 412, a 5' untranslated sequence comprising the first 102 nucleotides of exon 1; an initiation codon at nucleotide position 456; an N-terminal cytoplasmic tail of the protein encoded by the remainder of exon 1 and a portion of exon 2; four transmembrane (TM) regions encoded by exons 2 and 3 (TM-1), exons 3 and 4 (TM-2), exon 5 (TM-3), and exon 6 (TM-4); a C-terminal cytoplasmic tail and 3' untranslated region encoded by exon 7; and an ITAM motif in the C- terminal cytoplasmic
- Atopy is a common familial disorder caused by genetic and environmental factors. Atopy is characterized by exaggerated T- helper cell type II lymphocyte responses to common allergens, such as pollens and dust mites, with sustained, enhanced production of IgE. Allergy, asthma, rhinitis, and eczema are atopic hypersensitivity diseases. IgE binds to the high affinity IgE receptor presented on mucosal mast cells and basophils. IgE binding of allergens activates the receptor and initiates a cascade, leading to cellular release of inflammatory mediators.
- Dysregulation of the normal immediate hypersensitivity response results in abnormally high and sustained IgE serum levels and leads to mucosal inflammation. Atopy is detected by elevated total serum IgE levels, positive skin prick tests to common allergens, and specific serum IgE against these allergens. All three have been strongly correlated with each other and the presence of the symptoms of allergic reaction— wheezing, coughing, sneezing, and nasal blockage. Approximately 20% of the world population is affected by allergies, with over 50% of western populations testing positive to skin prick tests of one or more common allergens. Up to 10% of children suffer from atopic asthma, accounting for approximately one-third of US pediatric emergency room visits.
- Shirakawa et al (Lancet 347: 394-395, 1996) identified an Rsal restriction fragment length polymo ⁇ hism (RFLP) in the second intron, as well as three single nucleotide polymo ⁇ hisms (SNPs) in the sixth exon of the gene (Shirakawa et al., Nature Genet. 7:125-130; Shirakawa et al., Hum. Mol Genet. 5: 1129-1130).
- the exact site of the Rsal RFLP was not published, but association with atopic asthma, rhinitis, and eczema was found in a Japanese clinical population.
- polymo ⁇ hic sites correspond to the following nucleotide positions in the indicated GenBank Accession Number: 266 (PS2), 1456 (PS3), 2253 (PS4), 2302 (PS5), 5128 (PS6), 5173 (PS7), 5232 (PS8), 5252 (PS9), 5256 (PS10), 7402 (PS12) and 7446 (PS13) in M89796.1.
- the polymo ⁇ hisms at these sites are guanine or adenine at PS2, cytosine or thymine at PS3, guanine or cytosine at PS4, thymine or cytosine at PS5, cytosine or thymine at PS6, adenine or guanine at PS7, thymine or guanine at PS8, thymine or guanine at PS9, guanine or adenine at PS 10, thymine or cytosine at PS 12 and cytosine or thymine at PS 13.
- the inventors have determined the identity of the alternative nucleotides present at these sites, as well as at the previously identified sites at nucleotides 245 (PSl) and 7297 (PSl 1) in M89796.1. It is believed that IGERB-encoding polynucleotides containing one or more of the novel polymo ⁇ hic sites reported herein will be useful in studying the expression and biological function of IGERB, as well as in developing drugs targeting this protein. In addition, information on the combinations of polymo ⁇ hisms in the IGERB gene may have diagnostic and forensic applications.
- the invention provides an isolated polynucleotide comprising a nucleotide sequence which is a polymo ⁇ hic variant of a reference sequence for the IGERB gene or a fragment thereof.
- the reference sequence comprises SEQ ID NO: 1 and the polymo ⁇ hic variant comprises at least one polymo ⁇ hism selected from the group consisting of adenine at PS2, thymine at PS3, cytosine at PS4, cytosine at PS5, thymine at PS6, guanine at PS7, guanine at PS8, guanine at PS9, adenine at PS 10, cytosine at PS 12 and thymine at PS 13.
- the polymo ⁇ hic variant comprises one or more additional polymo ⁇ hisms selected from the group consisting of thymine at PS 1 and guanine at PS 11.
- a particularly preferred polymo ⁇ hic variant is a naturally-occurring isoform (also referred to herein as an "isogene") of the IGERB gene.
- An IGERB isogene of the invention comprises cytosine or thymine at PSl, guanine or adenine at PS2, cytosine or thymine at PS3, guanine or cytosine at PS4, thymine or cytosine at PS5, cytosine or thymine at PS6, adenine or guanine at PS7, thymine or guanine at PS8, thymine or guanine at PS9, guanine or adenine at PS 10, adenine or guanine at PSl 1, thymine or cytosine at PS 12 and cytosine or thymine at PS 13.
- the invention also provides a collection of IGERB isogenes, referred to herein as an IGERB genome anthology.
- An IGERB isogene may be defined by the combination and order of these polymo ⁇ hisms in the isogene, which is referred to herein as an IGERB haplotype.
- the invention also provides data on the number of different IGERB haplotypes found in the above four population groups. This haplotype data is useful in methods for deriving an IGERB haplotype from an individual's genotype for the IGERB gene and for determining an association between an IGERB haplotype and a particular trait.
- the invention provides a polynucleotide comprising a polymo ⁇ hic variant of a reference sequence for an IGERB cDNA or a fragment thereof.
- the reference sequence comprises SEQ ID NO:2 (Fig. 2) and the polymo ⁇ hic cDNA comprises at least one polymo ⁇ hism selected from the group consisting of thymine at a position corresponding to nucleotide 132, thymine at a position corresponding to nucleotide 428, guanine at a position corresponding to nucleotide 473, and guanine at a position corresponding to nucleotide 532 .
- the polymo ⁇ hic variant comprises an additional polymo ⁇ hism of guanine at a position corresponding to nucleotide 710.
- Polynucleotides complementary to these IGERB genomic and cDNA variants are also provided by the invention.
- the invention provides a recombinant expression vector comprising one of the polymo ⁇ hic genomic variants operably linked to expression regulatory elements as well as a recombinant host cell transformed or transfected with the expression vector.
- the recombinant vector and host cell may be used to express IGERB for protein structure analysis and drug binding studies.
- the invention provides a polypeptide comprising a polymo ⁇ hic variant of a reference amino acid sequence for the IGERB protein.
- the reference amino acid sequence comprises SEQ ID NO:3 (Fig.
- the polymo ⁇ hic variant comprises at least one variant amino acid selected from the group consisting of methionine at a position corresponding to amino acid position 143, cysteine at a position corresponding to amino acid position 158, and alanine at a position corresponding to amino acid position 178 .
- the polymo ⁇ hic variant also comprises glycine at a position corresponding to amino acid position 237.
- a polymo ⁇ hic variant of IGERB is useful in studying the effect of the variation on the biological activity of IGERB as well as studying the binding affinity of candidate drugs targeting IGERB for the treatment of diseases involving immune response.
- the present invention also provides antibodies that recognize and bind to the above polymo ⁇ hic IGERB protein variant. Such antibodies can be utilized in a variety of diagnostic and prognostic formats and therapeutic methods.
- the invention provides methods, compositions, and kits for haplotyping and/or genotyping the IGERB gene in an individual.
- the methods involve identifying the nucleotide or nucleotide pair present at one or more polymo ⁇ hic sites selected from PS2, PS3, PS4, PS5, PS6, PS7, PS8, PS9, PS10, PS12, and PS13 in one or both copies of the IGERB gene from the individual.
- the compositions contain oligonucleotide probes and primers designed to specifically hybridize to one or more target regions containing, or that are adjacent to, a polymo ⁇ hic site.
- the methods and compositions for establishing the genotype or haplotype of an individual at the novel polymo ⁇ hic sites described herein are useful for studying the effect of the polymo ⁇ hisms in the etiology of diseases affected by the expression and function of the IGERB protein, studying the efficacy of drugs targeting IGERB, predicting individual susceptibility to diseases affected by the expression and function of the IGERB protein and predicting individual responsiveness to drugs targeting IGERB.
- the invention provides a method for identifying an association between a genotype or haplotype and a trait.
- the trait is susceptibility to a disease, severity of a disease, the staging of a disease or response to a drug. Such methods have applicability in developing diagnostic tests and therapeutic treatments for diseases involving immune response.
- the present invention also provides transgenic animals comprising one of the IGERB genomic polymo ⁇ hic variants described herein and methods for producing such animals.
- the transgenic animals are useful for studying expression of the IGERB isogenes in vivo, for in vivo screening and testing of drugs targeted against IGERB protein, and for testing the efficacy of therapeutic agents and compounds for diseases involving immune response in a biological system.
- the present invention also provides a computer system for storing and displaying polymo ⁇ hism data determined for the IGERB gene.
- the computer system comprises a computer processing unit; a display; and a database containing the polymo ⁇ hism data.
- the polymo ⁇ hism data includes the polymo ⁇ hisms, the genotypes and the haplotypes identified for the IGERB gene in a reference population.
- the computer system is capable of producing a display showing IGERB haplotypes organized according to their evolutionary relationships.
- Figure 1 illustrates a reference sequence for the IGERB gene (Genbank Version Number M89796.1.1; contiguous lines; SEQ ID NO:l), with the start and stop positions of each region of coding sequence indicated below the sequence by the numbers within the brackets and the polymo ⁇ hic sites and polymo ⁇ hisms identified by Applicants in a reference population indicated by the variant nucleotide positioned below the polymo ⁇ hic site in the sequence.
- Figure 2 illustrates a reference sequence for the IGERB coding sequence (contiguous lines; SEQ ID NO:2), with the polymo ⁇ hic sites and polymo ⁇ hisms identified by Applicants in a reference population indicated by the variant nucleotide positioned below the polymo ⁇ hic site in the sequence.
- Figure 3 illustrates a reference sequence for the IGERB protein (contiguous lines; SEQ ID NO:3), with the variant amino acids caused by the polymo ⁇ hisms of Fig. 2 positioned below the polymo ⁇ hic site in the sequence.
- the present invention is based on the discovery of novel variants of the IGERB gene.
- the inventors herein discovered 11 novel polymo ⁇ hic sites by characterizing the IGERB gene found in genomic DNAs isolated from Index Repository IA that contains immortalized cell lines from one chimpanzee and 93 human individuals and Index Repository IB that contains 70 human individuals. These two repositories contain 10 individuals in common.
- Index Repository IA included a reference population of 79 unrelated individuals self-identified as belonging to one of four major population groups: Caucasian (22 individuals), African descent (20 individuals) Asian (20 individuals) Hispanic/Latino (17 individuals). To the extent possible, the members of this reference population were organized into population subgroups by the self-identified ethnogeographic origin of their four grandparents as shown in Table 1 below. In addition, Index Repository IA contains three unrelated indigenous American Indians (one from each of North, Central and South America), one three-generation Caucasian family (from the CEPH Utah cohort) and one two-generation African- American family.
- Index Repository IB contains a reference population of 70 human individuals comprised of 4 three-generation families (from the CEPH Utah cohort) as well as unrelated African- American, Asian and Caucasian individuals. A total of 38 individuals in this reference population are unrelated.
- the IGERB genotypes identified in Index Repository 1 A include those shown in Tables 4 and 5, respectively.
- the polymo ⁇ hism and haplotype data disclosed herein are useful for studying population diversity, anthropological lineage, the significance of diversity and lineage at the phenotypic level, paternity testing, forensic applications, and for identifying associations between the IGERB genetic variation and a trait such as level of drug response or susceptibility to disease.
- the following terms shall be defined as follows unless otherwise indicated:
- Allele - A particular form of a genetic locus, distinguished from other forms by its particular nucleotide sequence.
- Candidate Gene - A gene which is hypothesized to be responsible for a disease, condition, or the response to a treatment, or to be correlated with one of these.
- Gene - A segment of DNA that contains all the information for the regulated biosynthesis of an RNA product, including promoters, exons, introns, and other untranslated regions that control expression.
- Genotype An unphased 5 ' to 3 ' sequence of nucleotide pair(s) found at one or more polymo ⁇ hic sites in a locus on a pair of homologous chromosomes in an individual.
- genotype includes a full-genotype and/or a sub-genotype as described below.
- Full-genotype The unphased 5' to 3' sequence of nucleotide pairs found at all known polymo ⁇ hic sites in a locus on a pair of homologous chromosomes in a single individual.
- Sub-genotype The unphased 5' to 3' sequence of nucleotides seen at a subset of the known polymo ⁇ hic sites in a locus on a pair of homologous chromosomes in a single individual.
- Genotyping A process for determining a genotype of an individual.
- Haplotype - A 5 ' to 3 ' sequence of nucleotides found at one or more polymo ⁇ hic sites in a locus on a single chromosome from a single individual.
- haplotype includes a full- haplotype and/or a sub-haplotype as described below.
- Full-haplotype The 5 ' to 3 ' sequence of nucleotides found at all known polymo ⁇ hic sites in a locus on a single chromosome from a single individual.
- Sub-haplotype The 5 ' to 3 ' sequence of nucleotides seen at a subset of the known polymo ⁇ hic sites in a locus on a single chromosome from a single individual.
- Haplotype pair The two haplotypes found for a locus in a single individual.
- Haplotyping A process for determining one or more haplotypes in an individual and includes use of family pedigrees, molecular techniques and/or statistical inference.
- Haplotype data Information concerning one or more of the following for a specific gene: a listing of the haplotype pairs in each individual in a population; a listing of the different haplotypes in a population; frequency of each haplotype in that or other populations, and any known associations between one or more haplotypes and a trait.
- Isoform - A particular form of a gene, mRNA, cDNA or the protein encoded thereby, distinguished from other forms by its particular sequence and/or structure.
- Isogene - One of the isoforms of a gene found in a population. An isogene contains all of the polymo ⁇ hisms present in the particular isoform of the gene.
- Isolated - As applied to a biological molecule such as RNA, DNA, oligonucleotide, or protein, isolated means the molecule is substantially free of other biological molecules such as nucleic acids, proteins, lipids, carbohydrates, or other material such as cellular debris and growth media. Generally, the term "isolated" is not intended to refer to a complete absence of such material or to absence of water, buffers, or salts, unless they are present in amounts that substantially interfere with the methods of the present invention.
- Locus - A location on a chromosome or DNA molecule corresponding to a gene or a physical or phenotypic feature.
- Naturally-occurring - A term used to designate that the object it is applied to, e.g., naturally- occurring polynucleotide or polypeptide, can be isolated from a source in nature and which has not been intentionally modified by man.
- Nucleotide pair The nucleotides found at a polymo ⁇ hic site on the two copies of a chromosome from an individual.
- phased As applied to a sequence of nucleotide pairs for two or more polymo ⁇ hic sites in a locus, phased means the combination of nucleotides present at those polymo ⁇ hic sites on a single copy of the locus is known.
- Polymorphic site (PS) - A position within a locus at which at least two alternative sequences are found in a population, the most frequent of which has a frequency of no more than 99%.
- Polymorphism The sequence variation observed in an individual at a polymo ⁇ hic site.
- Polymo ⁇ hisms include nucleotide substitutions, insertions, deletions and microsatellites and may, but need not, result in detectable differences in gene expression or protein function.
- Polymorphism data Information concerning one or more of the following for a specific gene: location of polymo ⁇ hic sites; sequence variation at those sites; frequency of polymo ⁇ hisms in one or more populations; the different genotypes and/or haplotypes determined for the gene; frequency of one or more of these genotypes and/or haplotypes in one or more populations; any known association(s) between a trait and a genotype or a haplotype for the gene.
- Polymorphism Database A collection of polymo ⁇ hism data arranged in a systematic or methodical way and capable of being individually accessed by electronic or other means.
- Polynucleotide - A nucleic acid molecule comprised of single-stranded RNA or DNA or comprised of complementary, double-stranded DNA.
- Reference Population A group of individuals sharing a common ethnogeographic origin.
- Reference Population A group of subjects or individuals who are predicted to be representative of the genetic variation found in the general population.
- the reference population represents the genetic variation in the population at a certainty level of at least 85%, preferably at least 90%, more preferably at least 95% and even more preferably at least 99%.
- SNP Single Nucleotide Polymorphism
- Subject A human individual whose genotypes or haplotypes or response to treatment or disease state are to be determined.
- Treatment A stimulus administered internally or externally to a subject.
- Unphased - As applied to a sequence of nucleotide pairs for two or more polymo ⁇ hic sites in a locus, unphased means the combination of nucleotides present at those polymo ⁇ hic sites on a single copy of the locus is not known.
- the inventors herein have discovered 11 novel polymo ⁇ hic sites in the IGERB gene.
- the polymo ⁇ hic sites identified by the inventors are referred to as PS 1-13 to designate the order in which they are located in the gene (see Table 3 below), with the novel polymo ⁇ hic sites referred to as PS2, PS3, PS4, PS5, PS6, PS7, PS8, PS9, PS10, PS12, and PS13.
- the invention provides an isolated polynucleotide comprising a polymo ⁇ hic variant of the IGERB gene or a fragment of the gene which contains at least one of the novel polymo ⁇ hic sites described herein.
- the nucleotide sequence of a variant IGERB gene is identical to the reference genomic sequence for those portions of the gene examined, as described in the Examples below, except that it comprises a different nucleotide at one or more of the novel polymo ⁇ hic sites PS2, PS3, PS4, PS5, PS6, PS7, PS8, PS9, PS10, PS12, and PS13, and may also comprise one or more additional polymo ⁇ hisms selected from the group consisting of thymine at PSl and guanine at PSl 1 .
- nucleotide sequence of a variant fragment of the IGERB gene is identical to the corresponding portion of the reference sequence except for having a different nucleotide at one or more of the novel polymo ⁇ hic sites described herein.
- the invention specifically does not include polynucleotides comprising a nucleotide sequence identical to the reference sequence (or other reported IGERB sequences) or to portions of the reference sequence (or other reported IGERB sequences), except for genotyping oligonucleotides as described below.
- polymo ⁇ hism in a variant gene or fragment is identified by aligning its sequence against SEQ ID NO: 1.
- the polymo ⁇ hism is selected from the group consisting of adenine at PS2, thymine at PS3, cytosine at PS4, cytosine at PS5, thymine at PS6, guanine at PS7, guanine at PS8, guanine at PS9, adenine at PS10, cytosine at PS12 and thymine at PS13.
- the polymo ⁇ hic variant comprises a naturally-occurring isogene of the IGERB gene which is defined by any one of haplotypes 1-12 shown in Table 5 below.
- Polymo ⁇ hic variants of the invention may be prepared by isolating a clone containing the
- IGERB gene from a human genomic library.
- the clone may be sequenced to determine the identity of the nucleotides at the polymo ⁇ hic sites described herein. Any particular variant claimed herein could be prepared from this clone by performing in vitro mutagenesis using procedures well-known in the art.
- IGERB isogenes may be isolated using any method that allows separation of the two "copies" of the IGERB gene present in an individual, which, as readily understood by the skilled artisan, may be the same allele or different alleles. Separation methods include targeted in vivo cloning (TTVC) in yeast as described in WO 98/01573, U.S. Patent No. 5,866,404, and U.S. Patent No. 5,972,614.
- TTVC targeted in vivo cloning
- Another method which is described in U.S. Patent No. 5,972,614, uses an allele specific oligonucleotide in combination with primer extension and exonuclease degradation to generate hemizygous DNA targets.
- Yet other methods are single molecule dilution (SMD) as described in Ruano et al., Proc. Natl. Acad. Sci. 87:6296-6300, 1990; and allele specific PCR (Rua ⁇ o et al., 17 Nucleic Acids. Res. 8392, 1989; Ruano et al., 19 Nucleic Acids Res. 6877-6882, 1991; Michalatos-Beloin et al., 24 Nucleic Acids Res. 4841-4843, 1996).
- SMD single molecule dilution
- the invention also provides IGERB genome anthologies, which are collections of IGERB isogenes found in a given population.
- the population may be any group of at least two individuals, including but not limited to a reference population, a population group, a family population, a clinical population, and a same sex population.
- An IGERB genome anthology may comprise individual IGERB isogenes stored in separate containers such as microtest tubes, separate wells of a microtitre plate and the like. Alternatively, two or more groups of the IGERB isogenes in the anthology may be stored in separate containers.
- a preferred IGERB genome anthology of the invention comprises a set of isogenes defined by the haplotypes shown in Table 5 below.
- An isolated polynucleotide containing a polymo ⁇ hic variant nucleotide sequence of the invention may be operably linked to one or more expression regulatory elements in a recombinant expression vector capable of being propagated and expressing the encoded IGERB protein in a prokaryotic or a eukaryotic host cell.
- expression regulatory elements which may be used include, but are not limited to, the lac system, operator and promoter regions of phage lambda, yeast promoters, and promoters derived from vaccinia virus, adenovirus, retroviruses, or SV40.
- regulatory elements include, but are not limited to, appropriate leader sequences, termination codons, polyadenylation signals, and other sequences required for the appropriate transcription and subsequent translation of the nucleic acid sequence in a given host cell.
- the expression vector contains any additional elements necessary for its transfer to and subsequent replication in the host cell. Examples of such elements include, but are not limited to, origins of replication and selectable markers.
- Such expression vectors are commercially available or are readily constructed using methods known to those in the art (e.g., F. Ausubel et al., 1987, in "Current Protocols in Molecular Biology", John Wiley and Sons, New York, New York).
- Host cells which may be used to express the variant IGERB sequences of the invention include, but are not limited to, eukaryotic and mammalian cells, such as animal, plant, insect and yeast cells, and prokaryotic cells, such as E. coli, or algal cells as known in the art.
- the recombinant expression vector may be introduced into the host cell using any method known to those in the art including, but not limited to, microinjection, electroporation, particle bombardment, transduction, and transfection using DEAE-dextran, lipofection, or calcium phosphate (see e.g., Sambrook et al. (1989) in "Molecular Cloning. A Laboratory Manual", Cold Spring Harbor Press, Plainview, New York).
- eukaryotic expression vectors that function in eukaryotic cells, and preferably mammalian cells, are used.
- Non-limiting examples of such vectors include vaccinia virus vectors, adenovirus vectors, he ⁇ es virus vectors, and baculovirus transfer vectors.
- Preferred eukaryotic cell lines include COS cells, CHO cells, HeLa cells, NIH/3T3 cells, and embryonic stem cells (Thomson, J. A. et al., 1998 Science 282: 1145- 1147).
- Particularly preferred host cells are mammalian cells.
- polymo ⁇ hic variants of the IGERB gene will produce IGERB mRNAs varying from each other at any polymo ⁇ hic site retained in the spliced and processed mRNA molecules.
- These mRNAs can be used for the preparation of an IGERB cDNA comprising a nucleotide sequence which is a polymo ⁇ hic variant of the IGERB reference coding sequence shown in Figure 2.
- the invention also provides IGERB mRNAs and corresponding cDNAs which comprise a nucleotide sequence that is identical to SEQ ID NO:2 (Fig.
- RNA sequence except for having one or more polymo ⁇ hisms selected from the group consisting of thymine at a position corresponding to nucleotide 132, thymine at a position corresponding to nucleotide 428, guanine at a position corresponding to nucleotide 473, and guanine at a position corresponding to nucleotide 532, and may also comprise an additional polymo ⁇ hism of guanine at a position corresponding to nucleotide 710. Fragments of these variant mRNAs and cDNAs are included in the scope of the invention, provided they contain the novel polymo ⁇ hisms described herein.
- the invention specifically excludes polynucleotides identical to previously identified and characterized IGERB cDNAs and fragments thereof.
- Polynucleotides comprising a variant RNA or DNA sequence may be isolated from a biological sample using well-known molecular biological procedures or may be chemically synthesized.
- Genomic and cDNA fragments of the invention comprise at least one novel polymo ⁇ hic site identified herein and have a length of at least 10 nucleotides and may range up to the full length of the gene.
- a fragment according to the present invention is between 100 and 3000 nucleotides in length, and more preferably between 200 and 2000 nucleotides in length, and most preferably between 500 and 1000 nucleotides in length.
- nucleic acid molecules containing the IGERB gene may be complementary double stranded molecules and thus reference to a particular site on the sense strand refers as well to the corresponding site on the complementary antisense strand.
- reference may be made to the same polymo ⁇ hic site on either strand and an oligonucleotide may be designed to hybridize specifically to either strand at a target region containing the polymo ⁇ hic site.
- the invention also includes single-stranded polynucleotides which are complementary to the sense strand of the IGERB genomic variants described herein.
- Polynucleotides comprising a polymo ⁇ hic gene variant or fragment may be useful for therapeutic pu ⁇ oses.
- an expression vector encoding the isoform may be administered to the patient.
- the patient may be one who lacks the IGERB isogene encoding that isoform or may already have at least one copy of that isogene.
- IGERB IGERB isogene
- Expression of an IGERB isogene may be turned off by transforming a targeted organ, tissue or cell population with an expression vector that expresses high levels of untranslatable mRNA for the isogene.
- oligonucleotides directed against the regulatory regions (e.g., promoter, introns, enhancers, 3' untranslated region) of the isogene may block transcription. Oligonucleotides targeting the transcription initiation site, e.g., between positions -10 and +10 from the start site are preferred.
- inhibition of transcription can be achieved using oligonucleotides that base-pair with region(s) of the isogene DNA to form triplex DNA (see e.g., Gee et al. in Huber, B.E. and B.I. Carr, Molecular and Immunologic Approaches, Futura Publishing Co., Mt. Kisco, N.Y., 1994).
- Antisense oligonucleotides may also be designed to block translation of IGERB mRNA transcribed from a particular isogene. It is also contemplated that ribozymes may be designed that can catalyze the specific cleavage of IGERB mRNA transcribed from a particular isogene.
- the oligonucleotides may be delivered to a target cell or tissue by expression from a vector introduced into the cell or tissue in vivo or ex vivo.
- the oligonucleotides may be formulated as a pharmaceutical composition for administration to the patient.
- Oligoribonucleotides and/or oligodeoxynucleotides intended for use as antisense oligonucleotides may be modified to increase stability and half-life.
- Possible modifications include, but are not limited to phosphorothioate or 2' O-methyl linkages, and the inclusion of nontraditional bases such as inosine and queosine, as well as acetyl-, methyl-, thio-, and similarly modified forms of adenine, cytosine, guanine, thymine, and uracil which are not as easily recognized by endogenous nucleases.
- the invention also provides an isolated polypeptide comprising a polymo ⁇ hic variant of the reference IGERB amino acid sequence shown in Figure 3.
- the location of a variant amino acid in an IGERB polypeptide or fragment of the invention is identified by aligning its sequence against SEQ ID NO:3 (Fig. 3).
- An IGERB protein variant of the invention comprises an amino acid sequence identical to SEQ ID NO: 3 except for having one or more variant amino acids selected from the group consisting of methionine at a position corresponding to amino acid position 143, cysteine at a position corresponding to amino acid position 158, and alanine at a position corresponding to amino acid position 178, and may also comprise an additional variant amino acid of glycine at a position corresponding to amino acid position 237.
- IGERB protein variants included within the invention comprise all amino acid sequences based on SEQ ID NO: 3 and having the combination of amino acid variations described in Table 2 below.
- an IGERB protein variant of the invention is encoded by an isogene defined by one of the observed haplotypes shown in Table 5. Table2. Novel Polymo ⁇ hic Variant of IGERB
- the invention also includes IGERB peptide variants, which are any fragments of an IGERB protein variant that contains one or more of the amino acid variations shown in Table 2.
- An IGERB peptide variant is at least 6 amino acids in length and is preferably any number between 6 and 30 amino acids long, more preferably between 10 and 25, and most preferably between 15 and 20 amino acids long.
- Such IGERB peptide variants may be useful as antigens to generate antibodies specific for one of the above IGERB isoforms.
- the IGERB peptide variants may be useful in drug screening assays.
- an IGERB variant protein or peptide of the invention may be prepared by chemical synthesis or by expressing one of the variant IGERB genomic and cDNA sequences as described above.
- the IGERB protein variant may be isolated from a biological sample of an individual having an IGERB isogene which encodes the variant protein. Where the sample contains two different IGERB isoforms (i.e., the individual has different IGERB isogenes), a particular IGERB isoform of the invention can be isolated by immunoaffinity chromatography using an antibody which specifically binds to that particular IGERB isoform but does not bind to the other IGERB isoform.
- the expressed or isolated IGERB protein may be detected by methods known in the art, including Coomassie blue staining, silver staining, and Western blot analysis using antibodies specific for the isoform of the IGERB protein as discussed further below.
- IGERB variant proteins can be purified by standard protein purification procedures known in the art, including differential precipitation, molecular sieve chromatography, ion-exchange chromatography, isoelectric focusing, gel electrophoresis, affinity and immunoaffinity chromatography and the like. (Ausubel et. al., 1987, In
- a polymo ⁇ hic variant IGERB gene of the invention may also be fused in frame with a heterologous sequence to encode a chimeric IGERB protein.
- the non-IGERB portion of the chimeric protein may be recognized by a commercially available antibody.
- the chimeric protein may also be engineered to contain a cleavage site located between the IGERB and non-IGERB portions so that the IGERB protein may be cleaved and purified away from the non-IGERB portion.
- An additional embodiment of the invention relates to using a novel IGERB protein isoform in any of a variety of drug screening assays.
- Such screening assays may be performed to identify agents that bind specifically to all known IGERB protein isoforms or to only a subset of one or more of these isoforms.
- the agents may be from chemical compound libraries, peptide libraries and the like.
- the IGERB protein or peptide variant may be free in solution or affixed to a solid support.
- high throughput screening of compounds for binding to an IGERB variant may be accomplished using the method described in PCT application WO84/03565, in which large numbers of test compounds are synthesized on a solid substrate, such as plastic pins or some other surface, contacted with the IGERB protein(s) of interest and then washed. Bound IGERB protein(s) are then detected using methods well-known in the art.
- a novel IGERB protein isoform may be used in assays to measure the binding affinities of one or more candidate drugs targeting the IGERB protein.
- the invention provides antibodies specific for and immunoreactive with one or more of the novel IGERB variant proteins described herein.
- the antibodies may be either monoclonal or polyclonal in origin.
- the IGERB protein or peptide variant used to generate the antibodies may be from natural or recombinant sources or produced by chemical synthesis using synthesis techniques known in the art. If the IGERB protein variant is of insufficient size to be antigenic, it may be conjugated, complexed, or otherwise covalently linked to a carrier molecule to enhance the antigenicity of the peptide.
- carrier molecules include, but are not limited to, albumins (e.g., human, bovine, fish, ovine), and keyhole limpet hemocyanin (Basic and Clinical Immunology, 1991, Eds. D.P. Stites, and A.I. Terr, Appleton and Lange, Norwalk Connecticut, San Mateo, California).
- albumins e.g., human, bovine, fish, ovine
- keyhole limpet hemocyanin Basic and Clinical Immunology, 1991, Eds. D.P. Stites, and A.I. Terr, Appleton and Lange, Norwalk Connecticut, San Mateo, California.
- an antibody specifically immunoreactive with one of the novel IGERB protein isoforms described herein is administered to an individual to neutralize activity of the IGERB isoform expressed by that individual.
- the antibody may be formulated as a pharmaceutical composition which includes a pharmaceutically acceptable carrier.
- Antibodies specific for and immunoreactive with one of the novel IGERB protein isoforms described herein may be used to immunoprecipitate the IGERB protein variant from solution as well as react with IGERB protein isoforms on Western or immunoblots of polyacrylamide gels on membrane supports or substrates.
- the antibodies will detect IGERB protein isoforms in paraffin or frozen tissue sections, or in cells which have been fixed or unfixed and prepared on slides, coverslips, or the like, for use in immunocytochemical, immunohistochemical, and immunofluorescence techniques.
- an antibody specifically immunoreactive with one of the novel IGERB protein variants described herein is used in immunoassays to detect this variant in biological samples.
- an antibody of the present invention is contacted with a biological sample and the formation of a complex between the IGERB protein variant and the antibody is detected.
- suitable immunoassays include radioimmunoassay, Western blot assay, immunofluorescent assay, enzyme linked immunoassay (ELISA), chemiluminescent assay, immunohistochemical assay, immunocytochemical assay, and the like (see, e.g., Principles and Practice of Immunoassay, 1991, Eds. Christopher P. Price and David J.
- Neoman Stockton Press, New York, New York; Current Protocols in Molecular Biology, 1987, Eds. Ausubel et al., John Wiley and Sons, New York, New York).
- Standard techniques known in the art for ELISA are described in Methods in Immunodiagnosis, 2nd Ed., Eds. Rose and Bigazzi, John Wiley and Sons, New York 1980; and Campbell et al., 1984, Methods in Immunology, W.A. Benjamin, Inc.).
- Such assays may be direct, indirect, competitive, or noncompetitive as described in the art (see, e.g., Principles and Practice of Immunoassay, 1991, Eds. Christopher P. Price and David J.
- Proteins may be isolated from test specimens and biological samples by conventional methods, as described in Current Protocols in Molecular Biology, supra.
- Exemplary antibody molecules for use in the detection and therapy methods of the present invention are intact immunoglobulin molecules, substantially intact immunoglobulin molecules, or those portions of immunoglobulin molecules that contain the antigen binding site.
- Polyclonal or monoclonal antibodies may be produced by methods conventionally known in the art (e.g., Kohler and Milstein, 1975, Nature, 256:495-497; Campbell Monoclonal Antibody Technology, the Production and Characterization of Rodent and Human Hybridomas, 1985, In: Laboratory Techniques in Biochemistry and Molecular Biology, Eds. Burdon et al., Volume 13, Elsevier Science Publishers, Amsterdam).
- the antibodies or antigen binding fragments thereof may also be produced by genetic engineering.
- the technology for expression of both heavy and light chain genes in E. coli is the subject of PCT patent applications, publication number WO 901443, WO 901443 and WO 9014424 and in Huse et al., 1989, Science, 246: 1275-1281.
- the antibodies may also be humanized (e.g., Queen, C. et al. 1989 Proc. Natl. Acad. Sci. 86; 10029).
- Effect(s) of the polymo ⁇ hisms identified herein on expression of IGERB may be investigated by preparing recombinant cells and/or organisms, preferably recombinant animals, containing a ⁇ polymo ⁇ hic variant of the IGERB gene.
- expression includes but is not limited to one or more of the following: transcription of the gene into precursor mRNA; splicing and other processing of the precursor mRNA to produce mature mRNA; mRNA stability; translation of the mature mRNA into IGERB protein (including codon usage and tRNA availability); and glycosylation and/or other modifications of the translation product, if required for proper expression and function.
- the desired IGERB isogene may be introduced into the cell in a vector such that the isogene remains extrachromosomal. In such a situation, the gene will be expressed by the cell from the extrachromosomal location.
- the IGERB isogene is introduced into a cell in such a way that it recombines with the endogenous IGERB gene present in the cell. Such recombination requires the occurrence of a double recombination event, thereby resulting in the desired IGERB gene polymo ⁇ hism.
- Vectors for the introduction of genes both for recombination and for extrachromosomal maintenance are known in the art, and any suitable vector or vector construct may be used in the invention.
- IGERB isogene
- cells into which the IGERB isogene may be introduced include, but are not limited to, continuous culture cells, such as COS, NIH/3T3, and primary or culture cells of the relevant tissue type, i.e., they express the IGERB isogene.
- continuous culture cells such as COS, NIH/3T3, and primary or culture cells of the relevant tissue type, i.e., they express the IGERB isogene.
- Such recombinant cells can be used to compare the biological activities of the different protein variants.
- Recombinant organisms i.e., transgenic animals, expressing a variant IGERB gene are prepared using standard procedures known in the art.
- a construct comprising the variant gene is introduced into a nonhuman animal or an ancestor of the animal at an embryonic stage, i.e., the one-cell stage, or generally not later than about the eight-cell stage.
- Transgenic animals carrying the constructs of the invention can be made by several methods known to those having skill in the art.
- One method involves transfecting into the embryo a retrovirus constructed to contain one or more insulator elements, a gene or genes of interest, and other components known to those skilled in the art to provide a complete shuttle vector harboring the insulated gene(s) as a transgene, see e.g., U.S. Patent No. 5,610,053.
- Another method involves directly injecting a transgene into the embryo.
- a third method involves the use of embryonic stem cells. Examples of animals into which the IGERB isogenes may be introduced include, but are not limited to, mice, rats, other rodents, and nonhuman primates (see "The Introduction of Foreign Genes into Mice" and the cited references therein, In: Recombinant DNA, Eds. J.D. Watson, M.
- Transgenic animals stably expressing a human IGERB isogene and producing human IGERB protein can be used as biological models for studying diseases related to abnormal IGERB expression and/or activity, and for screening and assaying various candidate drugs, compounds, and treatment regimens to reduce the symptoms or effects of these diseases.
- An additional embodiment of the invention relates to pharmaceutical compositions for treating disorders affected by expression or function of a novel IGERB isogene described herein.
- the pharmaceutical composition may comprise any of the following active ingredients: a polynucleotide comprising one of these novel IGERB isogenes; an antisense oligonucleotide directed against one of the novel IGERB isogenes, a polynucleotide encoding such an antisense oligonucleotide, or another compound which inhibits expression of a novel IGERB isogene described herein.
- the composition contains the active ingredient in a therapeutically effective amount.
- composition also comprises a pharmaceutically acceptable carrier, examples of which include, but are not limited to, saline, buffered saline, dextrose, and water.
- a pharmaceutically acceptable carrier examples of which include, but are not limited to, saline, buffered saline, dextrose, and water.
- Those skilled in the art may employ a formulation most suitable for the active ingredient, whether it is a polynucleotide, oligonucleotide, protein, peptide or small molecule antagonist.
- the pharmaceutical composition may be administered alone or in combination with at least one other agent, such as a stabilizing compound.
- Administration of the pharmaceutical composition may be by any number of routes including, but not limited to oral, intravenous, intramuscular, intra- arterial, intramedullary, intrathecal, intraventricular, intradermal, transdermal, subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual, or rectal. Further details on techniques for formulation and administration may be found in the latest edition of Remington's Pharmaceutical Sciences (Maack Publishing Co., Easton, PA).
- the dose can be estimated initially either in cell culture assays or in animal models.
- the animal model may also be used to determine the appropriate concentration range and route of administration.
- Such information can then be used to determine useful doses and routes for administration in humans.
- the exact dosage will be determined by the practitioner, in light of factors relating to the patient requiring treatment, including but not limited to severity of the disease state, general health, age, weight and gender of the patient, diet, time and frequency of administration, other drugs being taken by the patient, and tolerance/response to the treatment.
- compositions and methods for detecting the novel IGERB polymo ⁇ hisms identified herein comprise at least one IGERB genotyping oligonucleotide.
- an IGERB genotyping oligonucleotide is a probe or primer capable of hybridizing to a target region that is located close to, or that contains, one of the novel polymo ⁇ hic sites described herein.
- oligonucleotide refers to a polynucleotide molecule having less than about 100 nucleotides.
- a preferred oligonucleotide of the invention is 10 to 35 nucleotides long. More preferably, the oligonucleotide is between 15 and 30, and most preferably, between 20 and 25 nucleotides in length.
- the oligonucleotide may be comprised of any phosphorylation state of ribonucleotides, deoxyribonucleotides, and acyclic nucleotide derivatives, and other functionally equivalent derivatives.
- oligonucleotides may have a phosphate-free backbone, which may be comprised of linkages such as carboxymethyl, acetamidate, carbamate, polyamide (peptide nucleic acid (PNA)) and the like (Varma, R. in Molecular Biology and Biotechnology, A
- Oligonucleotides of the invention may be prepared by chemical synthesis using any suitable methodology known in the art, or may be derived from a biological sample, for example, by restriction digestion.
- the oligonucleotides may be labeled, according to any technique known in the art, including use of radiolabels, fluorescent labels, enzymatic labels, proteins, haptens, antibodies, sequence tags and the like.
- Genotyping oligonucleotides of the invention must be capable of specifically hybridizing to a target region of an IGERB polynucleotide, i.e., an IGERB isogene.
- specific hybridization means the oligonucleotide forms an anti-parallel double-stranded structure with the target region under certain hybridizing conditions, while failing to form such a structure when incubated with a non-target region or a non-IGERB polynucleotide under the same hybridizing conditions.
- the oligonucleotide specifically hybridizes to the target region under conventional high stringency conditions.
- the skilled artisan can readily design and test oligonucleotide probes and primers suitable for detecting polymo ⁇ hisms in the IGERB gene using the polymo ⁇ hism information provided herein in conjunction with the known sequence information for the IGERB gene and routine techniques.
- a nucleic acid molecule such as an oligonucleotide or polynucleotide is said to be a "perfect” or “complete” complement of another nucleic acid molecule if every nucleotide of one of the molecules is complementary to the nucleotide at the corresponding position of the other molecule.
- a nucleic acid molecule is "substantially complementary” to another molecule if it hybridizes to that molecule with sufficient stability to remain in a duplex form under conventional low-stringency conditions. Conventional hybridization conditions are described, for example, by Sambrook J. et al., in Molecular Cloning, A Laboratory Manual, 2 nd Edition, Cold Spring Harbor Press, Cold Spring Harbor, NY ( 1989) and by Haymes, B.D.
- an oligonucleotide primer may have a non-complementary fragment at its 5 ' end, with the remainder of the primer being complementary to the target region.
- non-complementary nucleotides may be interspersed into the oligonucleotide probe or primer as long as the resulting probe or primer is still capable of specifically hybridizing to the target region.
- Preferred genotyping oligonucleotides of the invention are allele-specific oligonucleotides.
- ASO allele-specific oligonucleotide
- allele-specificity will depend upon a variety of readily optimized stringency conditions, including salt and formamide concentrations, as well as temperatures for both the hybridization and washing steps.
- Allele-specific oligonucleotide probes which usually provide good discrimination between different alleles are those in which a central position of the oligonucleotide probe aligns with the polymo ⁇ hic site in the target region (e.g., approximately the 7 th or 8 th position in a 15 mer, the 8 th or 9 th position in a 16mer, the 10 th or 11 th position in a 20 mer).
- a preferred ASO probe for detecting IGERB gene polymo ⁇ hisms comprises a nucleotide sequence, listed 5 ' to 3 ', selected from the group consisting of:
- ATCACAAGTAAAAGC (SEQ ID NO 4) and its complement
- ATCACAAATAAAAGC (SEQ ID NO 5) and its complement
- TTCCTTTTCCACTGT SEQ ID NO 16 and its complement
- TTCCTTTGCCACTGT SEQ ID NO 17 and its complement
- TTTTTTTTTGTGTGG (SEQ ID NO 18 and its complement
- TTTTTTTGTGTGTGG (SEQ ID NO 19 and its complement
- TTTTTGTGTGGGAAG SEQ ID NO 20 and its complement
- ATTTATTTGCCTGAT (SEQ ID NO 25 and its complement.
- An allele-specific oligonucleotide primer of the invention has a 3' terminal nucleotide, or preferably a 3' penultimate nucleotide, that is complementary to only one nucleotide of a particular SNP, thereby acting as a primer for polymerase-mediated extension only if the allele containing that nucleotide is present. Allele-specific oligonucleotide primers hybridizing to either the coding or noncoding strand are contemplated by the invention.
- a preferred ASO primer for detecting IGERB gene polymo ⁇ hisms comprises a nucleotide sequence, listed 5 ' to 3 ', selected from the group consisting of:
- CTATTCATCACAAAT (SEQ ID NO: 28) CAACAGGCTTTTATT ( SEQ I D NO : 29 )
- genotyping oligonucleotides of the invention hybridize to a target region located one to several nucleotides downstream of one of the novel polymo ⁇ hic sites identified herein. Such oligonucleotides are useful in polymerase-mediated primer extension methods for detecting one of the novel polymo ⁇ hisms described herein and therefore such genotyping oligonucleotides are referred to herein as "primer-extension oligonucleotides".
- the 3 '-terminus of a primer- extension oligonucleotide is a deoxynucleotide complementary to the nucleotide located immediately adjacent to the polymo ⁇ hic site.
- a particularly preferred oligonucleotide primer for detecting IGERB gene polymo ⁇ hisms by primer extension terminates in a nucleotide sequence, listed 5' to 3', selected from the group consisting of:
- TTCATCACAA (SEQ ID NO:70) CAGGCTTTTA (SEQ ID NO : 71 ) ; CGGCCTCATC (SEQ ID NO:72) GCAGTGGTGG (SEQ ID NO : 73 ) ; CCAGTATTAA (SEQ ID NO: 74) TAAATATCAT (SEQ ID NO : 75 ) ; ATATATAACA (SEQ ID NO:76) GAGCATATCT (SEQ ID NO : 77 ) ; GCTGGGGGAA (SEQ ID NO: 78) GGTAATTCCC (SEQ ID NO : 79 ) ; AGCTTGGCCT (SEQ ID NO: 80) GATGTGGATA (SEQ ID NO : 81 ) ; GGCTTCCTTT (SEQ ID NO:82) CATACAGTGG (SEQ ID NO : 83 ) ; GTATTTTTTT (SEQ ID NO: 84) TTCCCACACA (SEQ ID NO : 85 ) ;
- a composition contains two or more differently labeled genotyping oligonucleotides for simultaneously probing the identity of nucleotides at two or more polymo ⁇ hic sites. It is also contemplated that primer compositions may contain two or more sets of allele-specific primer pairs to allow simultaneous targeting and amplification of two or more regions containing a polymo ⁇ hic site. IGERB genotyping oligonucleotides of the invention may also be immobilized on or synthesized on a solid surface such as a microchip, bead, or glass slide (see, e.g., WO 98/20020 and WO 98/20019).
- Immobilized genotyping oligonucleotides may be used in a variety of polymo ⁇ hism detection assays, including but not limited to probe hybridization and polymerase extension assays.
- Immobilized IGERB genotyping oligonucleotides of the invention may comprise an ordered array of oligonucleotides designed to rapidly screen a DNA sample for polymo ⁇ hisms in multiple genes at the same time.
- the invention provides a kit comprising at least two genotyping oligonucleotides packaged in separate containers.
- the kit may also contain other components such as hybridization buffer (where the oligonucleotides are to be used as a probe) packaged in a separate container.
- the kit may contain, packaged in separate containers, a polymerase and a reaction buffer optimized for primer extension mediated by the polymerase, such as PCR.
- the above described oligonucleotide compositions and kits are useful in methods for genotyping and/or haplotyping the IGERB gene in an individual.
- the terms "IGERB genotype” and “IGERB haplotype” mean the genotype or haplotype contains the nucleotide pair or nucleotide, respectively, that is present at one or more of the novel polymo ⁇ hic sites described herein and may optionally also include the nucleotide pair or nucleotide present at one or more additional polymo ⁇ hic sites in the IGERB gene.
- the additional polymo ⁇ hic sites may be currently known polymo ⁇ hic sites or sites that are subsequently discovered.
- One embodiment of the genotyping method involves isolating from the individual a nucleic acid mixture comprising the two copies of the IGERB gene, or a fragment thereof, that are present in the individual, and determining the identity of the nucleotide pair at one or more of the polymo ⁇ hic sites selected from PS2, PS3, PS4, PS5, PS6, PS7, PS8, PS9, PS10, PS12, and PS13 in the two copies to assign an IGERB genotype to the individual.
- the two "copies" of a gene in an individual may be the same allele or may be different alleles.
- the identity of the nucleotide pair atone or more of the polymo ⁇ hic sites selected from the group consisting of PSl and PSl 1 is also determined.
- the genotyping method comprises determining the identity of the nucleotide pair at each of PS 1 - 13.
- the nucleic acid mixture is isolated from a biological sample taken from the individual, such as a blood sample or tissue sample.
- tissue samples include whole blood, semen saliva, tears, urine, fecal material, sweat, buccal, skin and hair.
- the nucleic acid mixture may be comprised of genomic DNA, mRNA, or cDNA and, in the latter two cases, the biological sample must be obtained from an organ in which the IGERB gene is expressed.
- mRNA or cDNA preparations would not be used to detect polymo ⁇ hisms located in introns or in 5' and 3' nontranscribed regions. If an IGERB gene fragment is isolated, it must contain the polymo ⁇ hic site(s) to be genotyped.
- One embodiment of the haplotyping method comprises isolating from the individual a nucleic acid molecule containing only one of the two copies of the IGERB gene, or a fragment thereof, that is present in the individual and determining in that copy the identity of the nucleotide at one or more of the polymo ⁇ hic sites PS2, PS3, PS4, PS5, PS6, PS7, PS8, PS9, PS10, PS12, and PS13 in that copy to assign an IGERB haplotype to the individual.
- the nucleic acid may be isolated using any method capable of separating the two copies of the IGERB gene or fragment such as one of the methods described above for preparing IGERB isogenes, with targeted in vivo cloning being the preferred approach.
- the haplotyping method also comprises identifying the nucleotide at one or more of the polymo ⁇ hic sites PSl and PS 11. In a particularly preferred embodiment, the nucleotide at each of PS 1 - 13 is identified.
- an IGERB haplotype pair is determined for an individual by identifying the phased sequence of nucleotides at one or more of the polymo ⁇ hic sites selected from PS2, PS3, PS4, PS5, PS6, PS7, PS8, PS9, PS10, PS12, and PS13 in each copy of the IGERB gene that is present in the individual.
- the haplotyping method comprises identifying the phased sequence of nucleotides at each of PS 1 - 13 in each copy of the IGERB gene.
- the identifying step is preferably performed with each copy of the gene being placed in separate containers.
- the two copies are labeled with different tags, or are otherwise separately distinguishable or identifiable, it could be possible in some cases to perform the method in the same container.
- first and second copies of the gene are labeled with different first and second fluorescent dyes, respectively, and an allele-specific oligonucleotide labeled with yet a third different fluorescent dye is used to assay the polymo ⁇ hic site(s), then detecting a combination of the first and third dyes would identify the polymo ⁇ hism in the first gene copy while detecting a combination of the second and third dyes would identify the polymo ⁇ hism in the second gene copy.
- the identity of a nucleotide (or nucleotide pair) at a polymo ⁇ hic site(s) may be determined by amplifying a target region(s) containing the polymo ⁇ hic site(s) directly from one or both copies of the IGERB gene, or fragment thereof, and the sequence of the amplified region(s) determined by conventional methods. It will be readily appreciated by the skilled artisan that only one nucleotide will be detected at a polymo ⁇ hic site in individuals who are homozygous at that site, while two different nucleotides will be detected if the individual is heterozygous for that site.
- the polymo ⁇ hism may be identified directly, known as positive-type identification, or by inference, referred to as negative-type identification.
- a site may be positively determined to be either guanine or cytosine for an individual homozygous at that site, or both guanine and cytosine, if the individual is heterozygous at that site.
- the site may be negatively determined to be not guanine (and thus cytosine/cytosine) or not cytosine (and thus guanine/guanine).
- the identity of the allele(s) present at any of the novel polymo ⁇ hic sites described herein may be indirectly determined by genotyping a polymo ⁇ hic site not disclosed herein that is in linkage disequilibrium with the polymo ⁇ hic site that is of interest. Two sites are said to be in linkage disequilibrium if the presence of a particular variant at one site enhances the predictability of another variant at the second site (Stevens, JC 1999, Mol. Diag. 4: 309-17). Polymo ⁇ hic sites in linkage disequilibrium with the presently disclosed polymo ⁇ hic sites may be located in regions of the gene or in other genomic regions not examined herein.
- Genotyping of a polymo ⁇ hic site in linkage disequilibrium with the novel polymo ⁇ hic sites described herein may be performed by, but is not limited to, any of the above-mentioned methods for detecting the identity of the allele at a polymo ⁇ hic site.
- the target region(s) may be amplified using any oligonucleotide-directed amplification method, including but not limited to polymerase chain reaction (PCR) (U.S. Patent No. 4,965,188), ligase chain reaction (LCR) (Barany et al., Proc. Natl. Acad. Sci.
- Oligonucleotide ligation assay OLA
- Oligonucleotides useful as primers or probes in such methods should specifically hybridize to a region of the nucleic acid that contains or is adjacent to the polymo ⁇ hic site.
- the oligonucleotides are between 10 and 35 nucleotides in length and preferably, between 15 and 30 nucleotides in length. Most preferably, the oligonucleotides are 20 to 25 nucleotides long.
- oligonucleotide The exact length of the oligonucleotide will depend on many factors that are routinely considered and practiced by the skilled artisan.
- Other known nucleic acid amplification procedures may be used to amplify the target region including transcription-based amplification systems (U.S. Patent No. 5,130,238; EP 329,822; U.S. Patent No. 5,169,766, WO89/06700) and isothermal methods (Walker et al., Proc. Natl. Acad. Sci. USA 89:392-396, 1992).
- a polymo ⁇ hism in the target region may also be assayed before or after amplification using one of several hybridization-based methods known in the art.
- allele-specific oligonucleotides are utilized in performing such methods.
- the allele-specific oligonucleotides may be used as differently labeled probe pairs, with one member of the pair showing a perfect match to one variant of a target sequence and the other member showing a perfect match to a different variant.
- more than one polymo ⁇ hic site may be detected at once using a set of allele- specific oligonucleotides or oligonucleotide pairs.
- the members of the set have melting temperatures within 5°C, and more preferably within 2°C, of each other when hybridizing to each of the polymo ⁇ hic sites being detected.
- Hybridization of an allele-specific oligonucleotide to a target polynucleotide may be performed with both entities in solution, or such hybridization may be performed when either the oligonucleotide or the target polynucleotide is covalently or noncovalently affixed to a solid support. Attachment may be mediated, for example, by antibody-antigen interactions, poly-L-Lys, streptavidin or avidin-biotin, salt bridges, hydrophobic interactions, chemical linkages, UV cross-linking baking, etc.
- Allele-specific oligonucleotides may be synthesized directly on the solid support or attached to the solid support subsequent to synthesis.
- Solid-supports suitable for use in detection methods of the invention include substrates made of silicon, glass, plastic, paper and the like, which may be formed, for example, into wells (as in 96-well plates), slides, sheets, membranes, fibers, chips, dishes, and beads.
- the solid support may be treated, coated or derivatized to facilitate the immobilization of the allele-specific oligonucleotide or target nucleic acid.
- the genotype or haplotype for the IGERB gene of an individual may also be determined by hybridization of a nucleic sample containing one or both copies of the gene to nucleic acid arrays and subarrays such as described in WO 95/11995.
- the arrays would contain a battery of allele-specific oligonucleotides representing each of the polymo ⁇ hic sites to be included in the genotype or haplotype.
- the identity of polymo ⁇ hisms may also be determined using a mismatch detection technique, including but not limited to the RNase protection method using riboprobes (Winter et al., Proc. Natl. Acad. Sci.
- variant alleles can be identified by single strand conformation polymo ⁇ hism
- SSCP serum-derived DNA sequence
- DGGE denaturing gradient gel electrophoresis
- a polymerase-mediated primer extension method may also be used to identify the polymo ⁇ hism(s).
- Another primer extension method is allele-specific PCR (Ruano et al., Nucl. Acids Res. 17:8392, 1989; Ruano et al., Nucl. Acids Res. 19, 6877-6882, 1991; WO 93/22456; Turki et al., J. Clin. Invest. 95:1635-1641, 1995).
- multiple polymo ⁇ hic sites may be investigated by simultaneously amplifying multiple regions of the nucleic acid using sets of allele-specific primers as described in Wallace et al. (WO89/10414).
- an individual's IGERB haplotype pair is predicted from its IGERB genotype using information on haplotype pairs known to exist in a reference population.
- the haplotyping prediction method comprises identifying an IGERB genotype for the individual at two or more polymo ⁇ hic sites selected from PS2, PS3, PS4, PS5, PS6, PS7, PS8, PS9, PS10, PS12, and PS13, enumerating all possible haplotype pairs which are consistent with the genotype, accessing data containing IGERB haplotype pairs identified in a reference population, and assigning a haplotype pair to the individual that is consistent with the data.
- the reference haplotype pairs include the IGERB haplotype pairs shown in Table 4.
- the reference population should be composed of randomly-selected individuals representing the major ethnogeographic groups of the world.
- a preferred reference population allows the detection of any haplotype whose frequency is at least 10% with about 99% certainty and comprises about 20 unrelated individuals from each of the four population groups named above.
- a particularly preferred reference population includes a 3-generation family representing one or more of the four population groups to serve as controls for checking quality of haplotyping procedures.
- the haplotype frequency data for each ethnogeographic group is examined to determine whether it is consistent with Hardy- Weinberg equilibrium. Hardy- Weinberg equilibrium (D.L.
- haplotyping the individual using a direct haplotyping method such as, for example, CLASPER System TM technology (U.S. Patent No. 5,866,404), SMD, or allele-specific long-range PCR (Michalotos-Beloin et al., Nucleic Acids Res. 24:4841-4843, 1996).
- CLASPER System TM technology U.S. Patent No. 5,866,404
- SMD SMD
- allele-specific long-range PCR Moichalotos-Beloin et al., Nucleic Acids Res. 24:4841-4843, 1996.
- the assigning step involves performing the following analysis. First, each of the possible haplotype pairs is compared to the haplotype pairs in the reference population. Generally, only one of the haplotype pairs in the reference population matches a possible haplotype pair and that pair is assigned to the individual. Occasionally, only one haplotype represented in the reference haplotype pairs is consistent with a possible haplotype pair for an individual, and in such cases the individual is assigned a haplotype pair containing this known haplotype and a new haplotype derived by subtracting the known haplotype from the possible haplotype pair.
- the individual is preferably haplotyped using a direct molecular haplotyping method such as, for example, CLASPER System TM technology (U.S. Patent No. 5,866,404), SMD, or allele-specific long-range PCR (Michalotos-Beloin et al., Nucleic Acids Res. 24:4841-4843, 1996).
- a direct molecular haplotyping method such as, for example, CLASPER System TM technology (U.S. Patent No. 5,866,404), SMD, or allele-specific long-range PCR (Michalotos-Beloin et al., Nucleic Acids Res. 24:4841-4843, 1996).
- the invention also provides a method for determining the frequency of an IGERB genotype or IGERB haplotype in a population.
- the method comprises determining the genotype or the haplotype pair for the IGERB gene that is present in each member of the population, wherein the genotype or haplotype comprises the nucleotide pair or nucleotide detected at one or more of the polymo ⁇ hic sites PS2, PS3, PS4, PS5, PS6, PS7, PS8, PS9, PS10, PS12, and PS13 in the IGERB gene; and calculating the frequency any particular genotype or haplotype is found in the population.
- the population may be a reference population, a family population, a same sex population, a population group, a trait population (e.g., a group of individuals exhibiting a trait of interest such as a medical condition or response to a therapeutic treatment).
- a trait population e.g., a group of individuals exhibiting a trait of interest such as a medical condition or response to a therapeutic treatment.
- frequency data for IGERB genotypes and/or haplotypes found in a reference population are used in a method for identifying an association between a trait and an IGERB genotype or an IGERB haplotype.
- the trait may be any detectable phenotype, including but not limited to susceptibility to a disease or response to a treatment.
- the method involves obtaining data on the frequency of the genotype(s) or haplotype(s) of interest in a reference population as well as in a population exhibiting the trait.
- Frequency data for one or both of the reference and trait populations may be obtained by genotyping or haplotyping each individual in the populations using one of the methods described above.
- the haplotypes for the trait population may be determined directly or, alternatively, by the predictive genotype to haplotype approach described above.
- the frequency data for the reference and/or trait populations is obtained by accessing previously determined frequency data, which may be in written or electronic form.
- the frequency data may be present in a database that is accessible by a computer.
- the frequencies of the genotype(s) or haplotype(s) of interest in the reference and trait populations are compared.
- the frequencies of all genotypes and/or haplotypes observed in the populations are compared. If a particular genotype or haplotype for the IGERB gene is more frequent in the trait population than in the reference population at a statistically significant amount, then the trait is predicted to be associated with that IGERB genotype or haplotype.
- the IGERB genotype or haplotype being compared in the trait and reference populations is selected from the full-genotypes and full-haplotypes shown in Tables 4 and 5, respectively, or from sub- genotypes and sub-haplotypes derived from these genotypes and haplotypes.
- the trait of interest is a clinical response exhibited by a patient to some therapeutic treatment, for example, response to a drug targeting IGERB or response to a therapeutic treatment for a medical condition.
- medical condition includes but is not limited to any condition or disease manifested as one or more physical and/or psychological symptoms for which treatment is desirable, and includes previously and newly identified diseases and other disorders.
- clinical response means any or all of the following: a quantitative measure of the response, no response, and adverse response (i.e., side effects).
- clinical population In order to deduce a correlation between clinical response to a treatment and an IGERB genotype or haplotype, it is necessary to obtain data on the clinical responses exhibited by a population of individuals who received the treatment, hereinafter the "clinical population".
- This clinical data may be obtained by analyzing the results of a clinical trial that has already been run and/or the clinical data may be obtained by designing and carrying out one or more new clinical trials.
- the term "clinical trial” means any research study designed to collect clinical data on responses to a particular treatment, and includes but is not limited to phase I, phase II and phase III clinical trials. Standard methods are used to define the patient population and to enroll subjects.
- the individuals included in the clinical population have been graded for the existence of the medical condition of interest. This is important in cases where the symptom(s) being presented by the patients can be caused by more than one underlying condition, and where treatment of the underlying conditions are not the same. An example of this would be where patients experience breathing difficulties that are due to either asthma or respiratory infections. If both sets were treated with an asthma medication, there would be a spurious group of apparent non-responders that did not actually have asthma. These people would affect the ability to detect any correlation between haplotype and treatment outcome.
- This grading of potential patients could employ a standard physical exam or one or more lab tests. Alternatively, grading of patients could use haplotyping for situations where there is a strong correlation between haplotype pair and disease susceptibility or severity.
- the therapeutic treatment of interest is administered to each individual in the trial population and each individual's response to the treatment is measured using one or more predetermined criteria. It is contemplated that in many cases, the trial population will exhibit a range of responses and that the investigator will choose the number of responder groups (e.g., low, medium, high) made up by the various responses.
- the IGERB gene for each individual in the trial population is genotyped and/or haplotyped, which may be done before or after administering the treatment.
- correlations between individual response and IGERB genotype or haplotype content are created. Correlations may be produced in several ways. In one method, individuals are grouped by their IGERB genotype or haplotype (or haplotype pair) (also referred to as a polymo ⁇ hism group), and then the averages and standard deviations of clinical responses exhibited by the members of each polymo ⁇ hism group are calculated.
- Correlations may also be analyzed using analysis of variation (ANOVA) techniques to determine how much of the variation in the clinical data is explained by different subsets of the polymo ⁇ hic sites in the IGERB gene.
- ANOVA analysis of variation
- PCT/USOO/17540 ANOVA is used to test hypotheses about whether a response variable is caused by or correlated with one or more traits or variables that can be measured (Fisher and vanBelle, supra, Ch. 10).
- a mathematical model may be readily constructed by the skilled artisan that predicts clinical response as a function of IGERB genotype or haplotype content.
- the model is validated in one or more follow-up clinical trials designed to test the model.
- the identification of an association between a clinical response and a genotype or haplotype (or haplotype pair) for the IGERB gene may be the basis for designing a diagnostic method to determine those individuals who will or will not respond to the treatment, or alternatively, will respond at a lower level and thus may require more treatment, i.e., a greater dose of a drug.
- the diagnostic method may take one of several forms: for example, a direct DNA test (i.e., genotyping or haplotyping one or more of the polymo ⁇ hic sites in the IGERB gene), a serological test, or a physical exam measurement. The only requirement is that there be a good correlation between the diagnostic test results and the underlying IGERB genotype or haplotype that is in turn correlated with the clinical response.
- this diagnostic method uses the predictive haplotyping method described above.
- Any or all analytical and mathematical operations involved in practicing the methods of the present invention may be implemented by a computer.
- the computer may execute a program that generates views (or screens) displayed on a display device and with which the user can interact to view and analyze large amounts of information relating to the IGERB gene and its genomic variation, including chromosome location, gene structure, and gene family, gene expression data, polymo ⁇ hism data, genetic sequence data, and clinical data population data (e.g., data on ethnogeographic origin, clinical responses, genotypes, and haplotypes for one or more populations).
- the IGERB polymo ⁇ hism data described herein may be stored as part of a relational database (e.g., an instance of an Oracle database or a set of ASCII flat files). These polymo ⁇ hism data may be stored on the computer's hard drive or may, for example, be stored on a CD ROM or on one or more other storage devices accessible by the computer. For example, the data may be stored on one or more databases in communication with the computer via a network.
- a relational database e.g., an instance of an Oracle database or a set of ASCII flat files.
- These polymo ⁇ hism data may be stored on the computer's hard drive or may, for example, be stored on a CD ROM or on one or more other storage devices accessible by the computer.
- the data may be stored on one or more databases in communication with the computer via a network.
- Example IA This example illustrates examination of various regions of the IGERB gene for polymo ⁇ hic sites using DNA for Index Repository IA.
- the following target regions of the IGERB gene were amplified using the PCR primer pairs listed below, with the sequences presented in the 5 ' to 3 ' direction and nucleotide positions shown for each region corresponding to the indicated GenBank Accession No.
- Amplification profile 94°C - 2 min. 1 cycle
- PCR products were purified by Solid Phase Reversible Immobilization using the protocol developed by the Whitehead Genome Center. A detailed protocol can be found at http://www.genome.wi.mit.edu/sequencing/protocols/pure/SPRI_pcr.html.
- the purified PCR products were sequenced in both directions using the primer sets described previously or those listed, in the 5 ' to 3 ' direction, below.
- Example IB This example illustrates examination of the IGERB gene for polymo ⁇ hic sites in a region spanning about 260 base pairs upstream of the ATG start codon to about 260 base pairs downstream of the termination codon.
- Target Regions PCR primer pairs which were designed based on GenBank Accession No. M89796, are set forth below:
- primer pairs were used in PCR reactions containing genomic DNA isolated from immortalized cell lines for each member of a reference population of 70 human individuals.
- the PCR reactions were carried out under the following conditions:
- Amplification profile 94°C - 2 min. 1 cycle
- PCR products were purified by Solid Phase Reversible Immobilization using the protocol developed by the Whitehead Genome Center. A detailed protocol can be found at http://www.genome.wi.mit.edu/sequencing/protocols/pure/SPRI_pcr.html.
- carboxyl coated magnetic beads (10 mg/ml) were washed three times with wash buffer (0.5 M EDTA, pH 8.0). Ten ⁇ l of washed beads and 50 ⁇ l of HYB BUFFER (2.5M NaCl/20% PEG 8000) were added to each PCR reaction mixture (50 ⁇ l). The reaction mixture was mixed well and incubated at RT for 10 min. The microtitre plate was placed on a magnet for 2 min and the beads washed twice with 150 ⁇ l of 70% EtOH. The beads were air dried for 2 min and resuspend in 20 ⁇ l of elution buffer (10 mM trisacetate, pH 7.8) and incubated at RT for 5 min. The beads were magnetically separated and the supernatant removed for testing and sequencing.
- wash buffer 0.5 M EDTA, pH 8.0
- Ten ⁇ l of washed beads and 50 ⁇ l of HYB BUFFER 2.5M NaCl/20% PEG 8000
- the purified PCR products were sequenced in both directions using the above PCR primer sets except where indicated below.
- This example illustrates analysis of the IGERB polymo ⁇ hisms identified in Index Repository IA for human genotypes and haplotypes for all polymo ⁇ hic sites except PS9 and PS10.
- the different genotypes containing these polymo ⁇ hisms that were observed in the reference population are shown in Table 4 below, with the haplotype pair indicating the combination of haplotypes determined for the individual using the haplotype derivation protocol described below.
- Table 4 homozygous positions are indicated by one nucleotide and heterozygous positions are indicated by two nucleotides.
- haplotype pairs shown in Table 4 were estimated from the unphased genotypes using an extension of Clark's algorithm (Clark, A.G. (1990) Mol Bio Evol 1, 111-122), as described in U.S. Provisional Application Serial No. 60/198,340 entitled "A Method and System for Determining Haplotypes from a Collection of Polymo ⁇ hisms".
- haplotypes are assigned directly from individuals who are homozygous at all sites or heterozygous at no more than one of the variable sites. This list of haplotypes is then used to deconvolute the unphased genotypes in the remaining (multiply heterozygous) individuals.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU69041/00A AU6904100A (en) | 1999-08-24 | 2000-08-11 | Drug target isogenes: polymorphisms in the immunoglobulin e receptor beta chain gene |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15042399P | 1999-08-24 | 1999-08-24 | |
US60/150,423 | 1999-08-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001014588A1 true WO2001014588A1 (fr) | 2001-03-01 |
Family
ID=22534457
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/022175 WO2001014588A1 (fr) | 1999-08-24 | 2000-08-11 | Isogenes cibles de medicament: polymorphismes dans le gene de la chaine beta du recepteur e d'immunoglobuline |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU6904100A (fr) |
WO (1) | WO2001014588A1 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005017505A2 (fr) * | 2003-08-14 | 2005-02-24 | Isis Innovation Limited | Diagnostic d'un trouble atopique |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995005481A1 (fr) * | 1993-08-18 | 1995-02-23 | Isis Innovation Limited | Procede de diagnostic et therapie |
US5625039A (en) * | 1991-12-24 | 1997-04-29 | Snow Brand Milk Products Co., Ltd. | Anti-human IgE monoclonal antibodies |
US5770396A (en) * | 1992-04-16 | 1998-06-23 | The United States Of America As Represented By The Department Of Health And Human Services | Isolation characterization, and use of the human beta subunit of the high affinity receptor for immunoglobulin E |
-
2000
- 2000-08-11 WO PCT/US2000/022175 patent/WO2001014588A1/fr active Application Filing
- 2000-08-11 AU AU69041/00A patent/AU6904100A/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5625039A (en) * | 1991-12-24 | 1997-04-29 | Snow Brand Milk Products Co., Ltd. | Anti-human IgE monoclonal antibodies |
US5770396A (en) * | 1992-04-16 | 1998-06-23 | The United States Of America As Represented By The Department Of Health And Human Services | Isolation characterization, and use of the human beta subunit of the high affinity receptor for immunoglobulin E |
WO1995005481A1 (fr) * | 1993-08-18 | 1995-02-23 | Isis Innovation Limited | Procede de diagnostic et therapie |
Non-Patent Citations (7)
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005017505A2 (fr) * | 2003-08-14 | 2005-02-24 | Isis Innovation Limited | Diagnostic d'un trouble atopique |
WO2005017505A3 (fr) * | 2003-08-14 | 2005-06-16 | Isis Innovation | Diagnostic d'un trouble atopique |
Also Published As
Publication number | Publication date |
---|---|
AU6904100A (en) | 2001-03-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2001023410A2 (fr) | Isogenes cibles a usage medicamenteux: polymorphismes dans le gene d'interleukine | |
WO2001004270A1 (fr) | Isogenes de ciblage de medicaments: polymorphismes dans le gene alpha du recepteur de l'interleukine 4 | |
WO2001005832A1 (fr) | Isogenes cibles de medicament: polymorphismes dans le gene d2 du recepteur de dopamine | |
WO2001090123A2 (fr) | Haplotypes du gene agtrl1 | |
WO2002012497A2 (fr) | Haplotypes du gene nfkbib | |
WO2001027312A2 (fr) | Isogenes cibles pour medicaments: polymorphismes dans le gene recepteur de l'acetylcholine muscarinique m1 | |
US20050196829A1 (en) | Haplotypes of the FCER1A gene | |
EP1208112A1 (fr) | Isogenes cibles pour medicament: polymorphismes dans le gene recepteur 1a de la 5-hydroxytryptamine | |
WO2001014588A1 (fr) | Isogenes cibles de medicament: polymorphismes dans le gene de la chaine beta du recepteur e d'immunoglobuline | |
WO2001079240A2 (fr) | Haplotypes du gene rangap1 | |
WO2002032928A2 (fr) | Haplotypes du gene hrh1 | |
WO2001029176A2 (fr) | Isogenes cibles de medicaments: polymorphismes dans le gene 3 muscarinique, de recepteur cholinergique | |
WO2002018657A1 (fr) | Haplotypes du gene d'or11a1 | |
WO2001079232A2 (fr) | Haplotypes du gene mpl | |
WO2002050098A2 (fr) | Haplotypes du gene du recepteur de la prolactine (prlr) | |
WO2002062820A2 (fr) | Haplotypes du gene cyp27b1 | |
WO2001090127A2 (fr) | Haplotypes du gene de hoxd3 | |
WO2001027313A2 (fr) | Isogenes cibles pour medicaments: polymorphisme dans le gene muscarinique 2 recepteur cholinergique | |
WO2002063045A1 (fr) | Isogenes cibles de medicament: polymorphismes dans le gene du recepteur 2 de l'angiotensine | |
WO2001018232A2 (fr) | Isogenes cibles de medicaments: polymorphismes dans le gene de proteine bruleuse de graisses excedentaires (mitochondriale, porteuse de protons) | |
WO2002030949A2 (fr) | Haplotypes du gene ltb4r | |
WO2001087908A2 (fr) | Haplotypes du gene ccr3 | |
WO2002026766A2 (fr) | Haplotypes du gene sstr4 | |
WO2002032924A2 (fr) | Haplotypes du gene chrm5 | |
WO2002022644A1 (fr) | Haplotypes du gene gpr7 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 09889866 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |